Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Research analysts at Raymond James cut their Q3 2025 earnings estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Tuesday, January 7th. Raymond James analyst M. Freeman now anticipates that the company will earn ($0.03) per share for the quarter, down from their prior estimate of $0.01. Raymond James currently has a "Strong-Buy" rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals' Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS and Q1 2026 earnings at $0.23 EPS.
Several other equities analysts have also recently weighed in on the stock. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the stock a "speculative buy" rating in a research report on Monday, September 30th. Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Two analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Medexus Pharmaceuticals currently has a consensus rating of "Strong Buy" and a consensus target price of C$5.25.
Get Our Latest Stock Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 0.7 %
Medexus Pharmaceuticals stock traded down C$0.03 during mid-day trading on Friday, hitting C$4.04. The company's stock had a trading volume of 305,268 shares, compared to its average volume of 107,668. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$4.24. The stock's fifty day moving average price is C$2.77 and its two-hundred day moving average price is C$2.53. The stock has a market capitalization of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
